31.4 C
New York
Friday, June 5, 2026

Tag: composite

Phase IIb Study Results of InnoCare’s Orelabrutinib in Patients with SLE Presented at 2026 EULAR

The study showed that orelabrutinib was safe and well tolerated in participants with SLE.

S&P Dow Jones Indices Consultation on Treatment of MegaCap Companies – Results

NEW YORK, June 4, 2026 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") conducted a consultation with market participants on potential changes to the S&P U.S....

Visionary Advances on Multiple Fronts at Pt. Leamington: Phase 2 Drilling Permits Submitted; Prospecting Permits Filed for ~30,000 Ha Regional Land Package; Field Personnel...

HighlightsExploration Permit Applications filed for:Phase 2 Diamond Drilling at the Pt. Leamington VMS Deposit targeting deposit resource upgrade / expansion of the emerging Kraken...

Visionary Advances on Multiple Fronts at Pt. Leamington: Phase 2 Drilling Permits Submitted; Prospecting Permits Filed for ~30,000 Ha Regional Land Package; Field Personnel...

HighlightsExploration Permit Applications filed for:Phase 2 Diamond Drilling at the Pt. Leamington VMS Deposit targeting deposit resource upgrade / expansion of the emerging Kraken...

FGR accelerates USA expansion & defence sector exposure with strategic acquisition of MITO® Material Solutions

HighlightsFGR enters binding agreement to acquire all assets, intellectual property, product lines and manufacturing capabilities of USA-based MITO® Material Solutions, Inc.Strategic acquisition expands FGR's...

FGR accelerates USA expansion & defence sector exposure with strategic acquisition of MITO® Material Solutions

HighlightsFGR enters binding agreement to acquire all assets, intellectual property, product lines and manufacturing capabilities of USA-based MITO® Material Solutions, Inc.Strategic acquisition expands FGR's...

FGR accelerates USA expansion & defence sector exposure with strategic acquisition of MITO® Material Solutions

HighlightsFGR enters binding agreement to acquire all assets, intellectual property, product lines and manufacturing capabilities of USA-based MITO® Material Solutions, Inc.Strategic acquisition expands FGR's...

TRREB: Spring Home Sales Stronger Than Last Year

TORONTO, June 03, 2026 (GLOBE NEWSWIRE) -- The Greater Toronto Area (GTA) resale housing market tightened in May 2026 compared to last year. Sales increased year-over-year, whereas new listings declined over the same period. As standing inventory has been absorbed, competition between buyers has likely increased in some neighbourhoods. This should see the price trend flatten and ultimately trend upwards in the months ahead. 

Johnson & Johnson late-breaking results show nipocalimab significantly reduced systemic lupus erythematosus (SLE) disease activity in a Phase 2 study

Nipocalimab – the first and only neonatal Fc receptor (FcRn) blocker to be studied in systemic lupus erythematosus – is designed to target and...

ASCO 2026 | Updated Data from an Oral Presentation of InnoCare’s Novel BCL2 Inhibitor Mesutoclax in MDS and AML Released

InnoCare's novel BCL2i mesutoclax in MDS and AML was released at 2026 ASCO as an oral presentation, demonstrating outstanding efficacy and safety.

Manufacturing PMI® at 54%; May 2026 ISM® Manufacturing PMI® Report

New Orders Growing; Production Growing; Employment Contracting; Supplier Deliveries Slowing; Raw Materials Inventories Contracting; Customers' Inventories Too Low; Prices Increasing; Imports Growing; Exports GrowingTEMPE,...

Faraday Future Reminds the Public That it Will Announce a Major Strategy Upgrade With its Dual-Flywheel & Dual-Bridge Eco Strategy on August 16th, at...

Faraday Future Reminds the Public That it Will Announce a Major Strategy Upgrade With its Dual-Flywheel & Dual-Bridge Eco Strategy on August 16

Canadian Home Sales Continue to Climb in July, National Benchmark Price Remains Steady

OTTAWA, Ontario, Aug. 15, 2025 (GLOBE NEWSWIRE) -- The number of home sales recorded over Canadian MLS® Systems climbed 3.8% on a month-over-month basis in July 2025. Building on gains recorded over the previous three months, transactions are now up a cumulative 11.2% since March.

Akero Therapeutics Announces Lancet Publication of the Phase 2b HARMONY Clinical Trial Demonstrating 96 Weeks Treatment with EFX Reduced Liver Fibrosis in Patients with...

Results support potential of efruxifermin (EFX) to reduce risk of fibrosis progression in patients with pre-cirrhotic (F2-F3) MASH
Results support potential of efruxifermin (EFX) to reduce risk of fibrosis progression in patients with pre-cirrhotic (F2-F3) MASH

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsComposite